Compare Iron Mountain Inc (IRM) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs ResMed Inc. — how do they compare? Iron Mountain Inc trades at $122.75 (market cap $36.44B), while ResMed Inc. trades at $225 (market cap $32.61B). The key difference: Iron Mountain Inc and ResMed Inc. are close in size by market cap, and Iron Mountain Inc pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| IRM | RMD | |
|---|---|---|
Market Cap | $36.44B | $32.61B |
Sector | Real Estate | Health |
52-Week High | $133.06 | $293.73 |
52-Week Low | $78.86 | $182.82 |
Enterprise Value | $55.85B | $31.97B |
Dividend Yield | 2.82% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $124.55, up 2.46% on the day, with a bearish technical signal but strong recent earnings beats. Revenue growth is robust, reaching $6.90B in 2025, though net margins are thin at 5.54%. The stock shows high valuation multiples, including a P/E of 86.8, and carries significant debt, with total liabilities at $18.94B. Analyst consensus is bullish with a $141.50 price target, supported by institutional buying and positive Q2 2026 results highlighted by data center growth.
Outlook is cautiously optimistic due to earnings momentum and data center expansion, but high debt and declining paper storage pose risks. The stock offers potential upside to the consensus target, yet investors must weigh valuation concerns against operational strengths.
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
